Paclitaxel binds and activates C5aR1: A new potential therapeutic target for the prevention of chemotherapy-induced peripheral neuropathy and hypersensitivity reactions.

MLA

Brandolini, Laura, et al. “Paclitaxel Binds and Activates C5aR1: A New Potential Therapeutic Target for the Prevention of Chemotherapy-Induced Peripheral Neuropathy and Hypersensitivity Reactions.” Cell Death & Disease, vol. 13, no. 5, May 2022, p. 500. EBSCOhost, https://doi.org/10.1038/s41419-022-04964-w.

APA

Brandolini, L., d’Angelo, M., Novelli, R., Castelli, V., Giorgio, C., Sirico, A., Cocchiaro, P., D’Egidio, F., Benedetti, E., Cristiano, C., Bugatti, A., Ruocco, A., Amendola, P. G., Talarico, C., Manelfi, C., Iaconis, D., Beccari, A., Quadros, A. U., Cunha, T. M., … Allegretti, M. (2022). Paclitaxel binds and activates C5aR1: A new potential therapeutic target for the prevention of chemotherapy-induced peripheral neuropathy and hypersensitivity reactions. Cell Death & Disease, 13(5), 500. https://doi.org/10.1038/s41419-022-04964-w

Chicago

Brandolini, Laura, Michele d’Angelo, Rubina Novelli, Vanessa Castelli, Cristina Giorgio, Anna Sirico, Pasquale Cocchiaro, et al. 2022. “Paclitaxel Binds and Activates C5aR1: A New Potential Therapeutic Target for the Prevention of Chemotherapy-Induced Peripheral Neuropathy and Hypersensitivity Reactions.” Cell Death & Disease 13 (5): 500. doi:10.1038/s41419-022-04964-w.